SG3 Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

SG3 Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,300	Closed	-$261K	–	305
2022 Q3	$261K	Buy	+6,300	New	+$324K	0.04%	184
2021 Q2	–	Sell	-58,300	Closed	-$6.64M	–	1271
2021 Q1	$6.64M	Sell	58,300 -35,800	-38%	-$4.87M	0.17%	132
2020 Q4	$13M	Buy	+94,100	New	+$11.2M	0.25%	89

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

SG3 Management's RARE Position: Q4 2022 in Review

SG3 Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2022, closing a stake of 32,173 shares — an estimated $1.33M sold.

SG3 Management first reported a position in RARE in Q2 2021 and held it in 3 quarters. The position peaked at $1.33M in Q3 2022. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

SG3 Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 32,173 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $1.33M.
SG3 Management first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 3 quarters.
SG3 Management's Ultragenyx Pharmaceutical position peaked at $1.33M in Q3 2022.
227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.